Biovica update - US progress
Redeye updates our Biovica outlook after reporting the full 2022/23. Biovica has secured two PPO contracts and the company is in progress to contract individual Hospitals and cancer centers. We make a smaller revision and the main value driver is additional contracts and the ability to to activate DiviTum use in Biovica’s expanding US network.. Our updated Base Case reflects a Base Case is SEK 28 ( 29) with a Bull of SEK 60 (50) and a Bear case of SEK 5 ( 7).
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/